Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections : a CRIOGO multicentre retrospective study
© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com..
OBJECTIVES: Staphylococcus epidermidis bone and joint infections (BJIs) on material are often difficult to treat. The activity of delafloxacin has not yet been studied on S. epidermidis in this context. The aim of this study was to assess its in vitro activity compared with other fluoroquinolones, against a large collection of S. epidermidis clinical strains.
METHODS: We selected 538 S. epidermidis strains isolated between January 2015 and February 2023 from six French teaching hospitals. One hundred and fifty-two strains were ofloxacin susceptible and 386 were ofloxacin resistant. Identifications were performed by MS and MICs were determined using gradient concentration strips for ofloxacin, levofloxacin, moxifloxacin and delafloxacin.
RESULTS: Ofloxacin-susceptible strains were susceptible to all fluoroquinolones. Resistant strains had higher MICs of all fluoroquinolones. Strains resistant to ofloxacin (89.1%) still showed susceptibility to delafloxacin when using the Staphylococcus aureus 2021 CA-SFM/EUCAST threshold of 0.25 mg/L. In contrast, only 3.9% of the ofloxacin-resistant strains remained susceptible to delafloxacin with the 0.016 mg/L S. aureus breakpoint according to CA-SFM/EUCAST guidelines in 2022. The MIC50 was 0.094 mg/L and the MIC90 was 0.38 mg/L.
CONCLUSIONS: We showed low delafloxacin MICs for ofloxacin-susceptible S. epidermidis strains and a double population for ofloxacin-resistant strains. Despite the absence of breakpoints for S. epidermidis, delafloxacin may be an option for the treatment of complex BJI, including strains with MICs of ≤0.094 mg/L, leading to 64% susceptibility. This study underlines the importance for determining specific S. epidermidis delafloxacin breakpoints for the management of BJI on material.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The Journal of antimicrobial chemotherapy - (2024) vom: 20. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tessier, E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/jac/dkae071 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369968786 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369968786 | ||
| 003 | DE-627 | ||
| 005 | 20240322001215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jac/dkae071 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369968786 | ||
| 035 | |a (NLM)38507272 | ||
| 035 | |a (PII)dkae071 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tessier, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections |b a CRIOGO multicentre retrospective study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. | ||
| 520 | |a OBJECTIVES: Staphylococcus epidermidis bone and joint infections (BJIs) on material are often difficult to treat. The activity of delafloxacin has not yet been studied on S. epidermidis in this context. The aim of this study was to assess its in vitro activity compared with other fluoroquinolones, against a large collection of S. epidermidis clinical strains | ||
| 520 | |a METHODS: We selected 538 S. epidermidis strains isolated between January 2015 and February 2023 from six French teaching hospitals. One hundred and fifty-two strains were ofloxacin susceptible and 386 were ofloxacin resistant. Identifications were performed by MS and MICs were determined using gradient concentration strips for ofloxacin, levofloxacin, moxifloxacin and delafloxacin | ||
| 520 | |a RESULTS: Ofloxacin-susceptible strains were susceptible to all fluoroquinolones. Resistant strains had higher MICs of all fluoroquinolones. Strains resistant to ofloxacin (89.1%) still showed susceptibility to delafloxacin when using the Staphylococcus aureus 2021 CA-SFM/EUCAST threshold of 0.25 mg/L. In contrast, only 3.9% of the ofloxacin-resistant strains remained susceptible to delafloxacin with the 0.016 mg/L S. aureus breakpoint according to CA-SFM/EUCAST guidelines in 2022. The MIC50 was 0.094 mg/L and the MIC90 was 0.38 mg/L | ||
| 520 | |a CONCLUSIONS: We showed low delafloxacin MICs for ofloxacin-susceptible S. epidermidis strains and a double population for ofloxacin-resistant strains. Despite the absence of breakpoints for S. epidermidis, delafloxacin may be an option for the treatment of complex BJI, including strains with MICs of ≤0.094 mg/L, leading to 64% susceptibility. This study underlines the importance for determining specific S. epidermidis delafloxacin breakpoints for the management of BJI on material | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Ruffier d'Epenoux, L |e verfasserin |4 aut | |
| 700 | 1 | |a Lartigue, M F |e verfasserin |4 aut | |
| 700 | 1 | |a Chaufour, L |e verfasserin |4 aut | |
| 700 | 1 | |a Plouzeau-Jayle, C |e verfasserin |4 aut | |
| 700 | 1 | |a Chenouard, R |e verfasserin |4 aut | |
| 700 | 1 | |a Guérin, F |e verfasserin |4 aut | |
| 700 | 1 | |a Tandé, D |e verfasserin |4 aut | |
| 700 | 1 | |a Lamoureux, C |e verfasserin |4 aut | |
| 700 | 1 | |a Bémer, P |e verfasserin |4 aut | |
| 700 | 1 | |a Corvec, S |e verfasserin |4 aut | |
| 700 | 0 | |a CRIOGO study group |e verfasserin |4 aut | |
| 700 | 1 | |a Abgueguen, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Caubrière, Marin |e investigator |4 oth | |
| 700 | 1 | |a Lemarie, Carole |e investigator |4 oth | |
| 700 | 1 | |a Chenouard, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Pailhories, Hélène |e investigator |4 oth | |
| 700 | 1 | |a Vildy, Amandine |e investigator |4 oth | |
| 700 | 1 | |a Ansart, Séverine |e investigator |4 oth | |
| 700 | 1 | |a Quaesaet, Luc |e investigator |4 oth | |
| 700 | 1 | |a Stindel, Eric |e investigator |4 oth | |
| 700 | 1 | |a Tandé, Didier |e investigator |4 oth | |
| 700 | 1 | |a Lamoureux, Claudie |e investigator |4 oth | |
| 700 | 1 | |a Greves, Anaïs |e investigator |4 oth | |
| 700 | 1 | |a Boutoille, David |e investigator |4 oth | |
| 700 | 1 | |a Lecomte, Raphaël |e investigator |4 oth | |
| 700 | 1 | |a Deschanvres, Colin |e investigator |4 oth | |
| 700 | 1 | |a Nich, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Crenn, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Bémer, Pascale |e investigator |4 oth | |
| 700 | 1 | |a Corvec, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Ruffier d'Epenoux, Louise |e investigator |4 oth | |
| 700 | 1 | |a Paquin, Axelle |e investigator |4 oth | |
| 700 | 1 | |a Grégoire, Matthieu |e investigator |4 oth | |
| 700 | 1 | |a Bourigault, Céline |e investigator |4 oth | |
| 700 | 1 | |a Plantard, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Cazenave-Roblot, France |e investigator |4 oth | |
| 700 | 1 | |a Le Moal, Gwenaël |e investigator |4 oth | |
| 700 | 1 | |a Pries, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Plouzeau-Jayle, Chloé |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Céline |e investigator |4 oth | |
| 700 | 1 | |a Arvieux, Cédric |e investigator |4 oth | |
| 700 | 1 | |a Baldeyrou, Marion |e investigator |4 oth | |
| 700 | 1 | |a Common, Harold |e investigator |4 oth | |
| 700 | 1 | |a Cattoir, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Reissier, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Méheut, Anne |e investigator |4 oth | |
| 700 | 1 | |a Bernard, Louis |e investigator |4 oth | |
| 700 | 1 | |a Lemaignen, Adrien |e investigator |4 oth | |
| 700 | 1 | |a Lacasse, Marion |e investigator |4 oth | |
| 700 | 1 | |a Rosset, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Le Nail, Louis-Romée |e investigator |4 oth | |
| 700 | 1 | |a Lartigue, Marie-Frédérique |e investigator |4 oth | |
| 700 | 1 | |a Laplaige, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Chaufour, Laura |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g (2024) vom: 20. März |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:20 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkae071 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 20 |c 03 | ||